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Prevalence of  hypovitaminosis D and its relation to cardiovascular 
risk among elderly diabetic female patients
Vitamin D deficiency is highly prevalent worldwide and certain 
groups as elderly persons women and institutionalized persons 
are particularly prone to severe deficiency. Objective: To identify 
the prevalence of hypovitaminosis D and its relation to cardio-
vascular risk among elderly diabetic female patients. Method: A 
cross sectional study conducted from the first of October 2014 
to the end of March, 2016, where 163 elderly diabetic females 
who attended Ain shams university hospital at that time were in-
cluded. They underwent careful history taking, body mass index 
calculation,  blood pressure measurement and Serum 25(OH) D 
measurement, assessment of insulin secretion including fasting 
serum C-peptide and CPI measurement in addition to assess-
ment of glycemic control by fasting blood sugar estimation. The 
level of 25 hydroxy vitamin D (25OHD) was measured. Results: 
The prevalence of vitamin D deficiency (25OHD level <20 ng/
mL ) and insufficiency (25OHD concentration of 20–29 ng/mL) 
among elderly Egyptian diabetic female patients are 71.2% and 
28.2% resp. There is statistically significant association be-
tween vitamin D deficiency and low fasting C peptide level and 
c peptide index. The 3 independent predictor of the presence 
of vitamin D deficiency were types of diabetic medications, low 
C-peptide and CPI values and upon logistic regression analysis 
for these 3 variables, lower CP level was an independent pre-
dictor of the presence of vitamin D deficiency. Results showed a 
weak negative correlation between serum 25(OH)D, systolic BP, 
BMI and  HOMA IR in studied subjects. Conclusion: Prevalence 
of vitamin D deficiency among elderly Egyptian diabetic female 
patients is 71.2%. There is statistically significant association be-
tween vitamin D deficiency and low  fasting C peptide level and c 
peptide index.
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INTRODUCTION 
Hypovitaminosis D has become pandemic and 
is now seen in every country in the world. It has 
been estimated that more than one billion 
people worldwide are either vitamin D deficient 
or insufficient [1]. Older people are more likely 
to have lower serum 25(OH)D concentrations 
[2], partly due to reduced ability to synthesize 
vitamins with increasing age [3]. 
Alarming levels of vitamin D deficiency among 
Egyptian females across all age groups have 
been demonstrated, prevalence of 
hypovitaminosis D is approximately 77.2% 
among healthy geriatric population [1]. There is 
evident relationship between vitamin D 
adequacy and various human disease including 
skeletal and extra skeletal manifestations. As it 
has a role in many metabolic processes such 
as glucose metabolism [4]. Prevalence of 
hypovitaminosis D among diabetic patients 
exceeds 80 % in various population, also 
vitamin D status is inversely related to glycemic 
control. Thus, a poor glycemic control is 
associated with low vitamin D levels [5], as 
25(OH)D plays an important role in glucose 
homeostasis via different mechanisms. It 
improves insulin sensitivity of the target cells 
(liver, skeletal muscle, and adipose tissue [6, 
7]. In addition, recent research suggests that 
low 25(OH)D concentrations may be related to 
insulin resistance [9].  
In addition to vitamin D role in the pathogenesis 
of DM, there is a growing body of evidence 
suggests that low levels of vitamin D may 
adversely affect the cardiovascular system 
through several mechanisms [10]. Analyzing 
data from the Third National Health and 
Nutrition Examination Survey (NHANES III) 
showed a strong association between 
hypovitaminosis D and cardiovasular risk 
factors including diabetes, high blood pressure 
and increased body mass index [11]. 
Hypovitaminosis D is associated with higher 
risk of metabolic syndrome, a cluster of 
abdominal obesity, hypertension, 
hyperglycemia and dyslipidemia which are a 
major risk factor for cardiovascular disease and 
mortality [12]. as it has an anti-inflammatory 
effect and negative regulator of the renin-
angiotensin system that decreases blood 
pressure [13]. 
Insulin resistance is a hallmark of diabetes, 
obesity, cardiovascular diseases and metabolic 
syndrome [14]. A number of indices have been 
used to simplify and improve the determination 
of insulin resistance [14]. Fasting C-peptide 
could be used for determination of Insulin 
resistance, using HOMA modeling [15], as C-
peptide concentrations in the peripheral blood 
are widely accepted as the most appropriate 
measure of insulin secretion because it is 
secreted in equimolar amounts with insulin [16, 
17]. C peptide index (CPI) could be used as an 
index of endogenous insulin secretion and 
insulin resistance, it is not affected by 
exogenous insulin therapy, hence its value in 
patients with insulin therapy [18]. 
The aim of this study was to identify the 
prevalence of hypovitaminosis D and to detect 
its relation to cardiovascular risk among 
Egyptian elderly diabetic female patients. 
SUBJECTS AND METHODS 
Study design: A cross sectional study. 
Setting: Inpatient wards, Ain Shams University 
Hospital. 
Study participants: One hundred and sixty-three 
elderly diabetic females recruited from the first 
of October 2014 to the end of March 2016.  
After obtaining an informed consent, all 
participants underwent careful history taking 
including history of DM and hypertension. All 
included patients were diabetics on antidiabetic 
treatment and the associated hypertension was 
evaluated based on history of hypertension and 
on blood pressure measurement with a 
calibrated  sphygmomanometer  at resting 
state, hypertension was  defined as a systolic 
pressure above or equal 140 mmHg and/or a 
diastolic pressure above or equal 90 mmHg 
[19]. Blood Samples were withdrawn during 
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fasting state after about 8 hours fasting, then 
collected into plain tubes and centrifuged to 
separate serum that is stored at -70°C until 
analysis then referred to Ain shams university 
hospital blood lab for determination of serum 
25(OH)D and fasting serum C-peptide.  
Serum 25(OH) D measurement was done using 
25(OH) D kits manufactured by DRG 
instruments GmbH, Marburg, Germany and 
were analyzed by ELISA methods. Level of 
25(OH) D equal or more than 30ng/ml is 
considered to be sufficient, 10 to less than 
30ng/ml is considered to be insufficient, and 
level less than 10ng/ml is considered as vitamin 
D deficiency [20]. 
Fasting serum C-peptide level was done using 
C-peptide kits manufactured by DRG 
instruments GmbH, Marburg, Germany and 
were analyzed by ELISA methods and 
according to the used C peptide kit, reference 
range was (0.5-3.2ng/ml), patients were divided 
into 3 categories:  
High CP level: Serum C-peptide level > 3.2 
indicating hyperinsulinemic state and insulin 
resistance, 
Normal CP level: Serum C-peptide level 0.5–
3.2  
Low CP level: Serum C-peptide level <0.5 
indicating insulin deficiency state. 
All patients underwent assessment of glycemic 
control by fasting blood sugar estimation 
utilizing enzyme technique with 
glucosooxidasis. Glycemic control was 
categorized based on FBS value, normal 
values were taken as less than 100 mg/dl 
(normal FBS category) and high in cases with 
value over or equal to 100 mg/dl (high FBS 
category).  
 Assessment of insulin resistance done by 
HOMA2-IR index which was obtained by the 
program HOMA Calculator v2.2.2 (The Oxford 
Centre for Diabetes. Endocrinology & 
Metabolism. Diabetes Trial Unit. HOMA 
Calculator. Available from: 
http://www.dtu.ox.ac.uk/ Accessed March 
2009). At the current study, HOMA 2 calculation 
couldn’t be done for 60 patients whose serum 
C-peptide level less than 0.6 ng/ml as this value 
is not accessible at the program so estimation 
of insulin resistance done for 103 patients only. 
HOMA-IR makes it possible to define persons 
with insulin resistance with a single glucose and 
C-peptide measurement in the fasting state, we 
used 2.0 as HOMA 2-IR cut-off point to 
diagnose insulin resistance. Patients with 
HOMA2-IR ≥ 2.0 were considered insulin 
resistant and patients with  HOMA2-IR index  < 
2 were not considered insulin resistant [21, 22].  
Estimation of B cell function, in addition to 
fasting serum C-peptide, CPI was used as an 
indicator for insulin secretion. CPI 
measurement was done for each participant. 
The C-peptide index (CPI) was calculated for all 
participants with the following formula: fasting 
C-peptide (ng/ml)/fasting glycemia (mg/dl) × 
100 [23, 24]. We used CPI value cut off point at 
1.1ng/ mg. Accordingly, patients were divided 
into 2 categories: 
High CPI: C-peptide index (CPI) value ≥ 1.1 
indicating hyperinsulinemic state and insulin 
resistance  
Low CPI: C-peptide index (CPI) value < 1.1 
indicating insulin deficiency state [25]. 
Ethical statement 
There is no conflict of interest of any kind, all 
authors have no financial or any other kind of 
personal conflicts.  
All authors meet the criteria for authorship and 
are in agreement with the content of the 




Values were presented as means + SD or as 
numbers and proportions, as appropriate. The 
relations between qualitative variables were 
evaluated by Chi-square test or Fisher’s exact 
test, as indicated. Means were compared with 
Student’s test or analysis of variance. 
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Quantitative variables were correlated with the 
use of coefficient of correlation “r”. Variables 
that were statistically significant in univariate 
analysis were introduced in a logistic regression 
model to detect independent predictors of 
outcome. All tests were bilateral and a P value 
of 5% was the limit of statistical significance. 
Analysis was performed by statistical package 
software IBM- SPSS for MAC, version 24.  
RESULTS:  
This study was conducted at Ain Shams 
university hospitals during the time period of 
about 2 years, 163 elderly diabetic females 
were enrolled in the study, 71.8% (117) were 
on insulin therapy and 28.2% (46) were on oral 
hypoglycemic medication. 
Estimation of B cell function and insulin 
resistance were done for 102 patients only as 
HOMA 2 calculation couldn’t be done for 60 
patients whose serum C-peptide levels were 
less than 0.6 ng / ml as this value is not 
accessible at the program.  
The study was conducted on 163 elderly 
diabetic females with a mean age of 66.19 
±5.72 years. Serum 25(OH)D was 9.01(±6.04), 
height was 153.68 cm (±7.22), weight was 
79.69 kg (±21.56), and BMI was 33.65 (±8.36). 
Systolic BP was 128.56 (±19.35), diastolic BP 
was 79.39 (±11.08), fasting blood sugar was 
174.20 (±84.58), serum C peptide (ng/mL) was 
2.77 (±3.62), CPI was 1.84 (±2.64) and HOMA 
IR was 4.13 (±4.09) (Table 1). Prevalence of 
vitamin D deficiency was 71.2%, vitamin D 
insufficiency was 28.2% and vitamin D 
sufficiency was 0.6% (the case with sufficient 
vitamin D was not enrolled in subsequent 
comparisons) (Table 2). 
There was statistically significant higher 
prevalence of vitamin D deficiency among 
diabetics on insulin therapy in comparison to 
those on oral hypoglycemic drugs. There was 
statistically significant difference between 
means of 25(OH)D as regards CP level and 
CPI.  Low fasting serum C peptide level and 
CPI were found to be significantly related to 
lower vitamin D level. Vitamin D deficiency was 
more common among obese patients 79 
person out of 110 (68.1%). In comparison to 
vitamin D insufficiency, vitamin D deficiency 
was significantly associated with the presence 
of lower CP level and CPI values. But there 
was no statistically significant difference 
between the 2 groups of vitamin D as regards 
presence of insulin resistance (Table 3). Upon 
logistic regression analysis done for the 3 
variables associated with vitamin D deficiency, 
lower CP level was an independent predictor of 
the presence of vitamin D deficiency (Table 4). 
There was statistically significant association 
between low C peptide level and presence of 
vitamin D deficiency (P value 0.000) (Figure 1). 
There was a positive correlation between 
serum 25(OH)D and C peptide (ng/mL) and CPI 
and negative correlation between serum 
25(OH)D and Systolic BP, BMI, and, HOMA IR, 
although not statistically significant. There was 
statistically significant difference between CP 
level categories as regards HOMA %B and 
HOMA IR. High CP level categories 
significantly associated with higher HOMA %B 
and HOMA IR. There was statistically 
significant association between high C peptide 
level and presence of insulin resistance (P 
value 0.000), as all patients (52) with high C 
peptide level are insulin resistant (Figure 2). 
Similarly, there was statistically significant 
difference between the 2 categories of CPI as 
regards fasting blood sugar, 25(OH)D (ng/mL), 
HOMA %B and HOMA IR. The lower CPI was 
significantly associated with lower 25(OH)D, C 
peptide, HOMA %B and HOMA IR (Table 5). 
There was significant association between high 
CPI and presence of Insulin resistance (P value 
0.000) (figure 3).  
There was no statistically significant difference 
between means of BMI as regards serum 
25(OH)D, but the majority of obese patients are 
vitamin D deficient (P value 0.34).  
Upon comparison between means of serum 25 
(OH) D (ng/mL) in uncontrolled and controlled 
Systolic blood pressure were 7.77± 4.41 vs.  
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9.29 ± 5.77 and means of serum 25 (OH) D 
(ng/mL) in uncontrolled and controlled Diastolic 
blood pressure were 8.53 ± 5.43 vs. 8.93 ±5.40, 
respectively without statistically significant 
difference.  
 
Table 1: The clinical characteristics of the study subjects 
Table 2:  Serum 25(OH)vitamin D levels among participants 









116 (71.20) 46 (28.20) 1 (0.60) 163 (100.00) 
Vitamin D deficiency (25OHD level <20 ng/mL ) and insufficiency (25OHD concentration of 20–29 ng/mL) 
 
Figure 1: Comparison between 25(OH)D deficiency-insufficiency as regards C peptide level. 
Variables  V.D (ng/mL) 
Descriptive Statistics 
Range Mean ± SD 
Age 60.00 - 85.00 66.19 ± 5.72 
Weight (kg) 33.00 - 225.00 79.69 ± 21.56 
Height (cm) 130.00 - 170.00 153.68 ± 7.22 
BMI 14.28 - 85.73 33.65 ± 8.36 
Systolic BP 80.00 - 210.00 128.56 ± 19.35 
Diastolic BP 50.00 - 100.00 79.39 ± 11.08 
Fasting blood sugar 43.00 - 460.00 174.20 ± 84.58 
C peptide (ng/mL) 0.001 - 19.55 2.77 ± 3.62 
C Peptide Index (CPI) 0.0005 - 19.78 1.84 ± 2.64 
Serum 25 OH Vit D (ng/mL) 0.01 - 44.00 9.01 ± 6.04 
HOMA %B 6.40 - 405.90 95.02 ± 81.29 
HOMA IR 0.48 - 31.25 4.13 ± 4.09 
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Table 3: Comparison between participants with sufficient and insufficient levels of 25(OH) 
vitamin D, stratified by CP level, CPI value and IR.   
Quantitative Variables 
Vitamin D status 
Chi-Square 
Deficiency Insufficiency Total 
N (116) % N (46) % N (162) % X2 P-value 
C Peptide level 
High 32.00 27.60 20.00 43.50 52.00 32.10 
33.948a 0.000 Normal 26.00 22.40 25.00 54.30 51.00 31.50 
Low 58.00 50.00 1.00 2.20 59.00 36.40 
C Peptide Index (CPI) value 
High 45.00 38.80 32.00 69.60 77.00 47.50 
12.507a 0.000 
Low 71.00 61.20 14.00 30.40 85.00 52.50 
Insulin resistance* 
Yes 39.00 56.50 30.00 43.50 69.00 67.60 
0.010a 1.000 
No 19.00 57.60 14.00 43.10 33.00 32.40 
Type of diabetic medication 
Insulin  90.00 77.60 27.00 58.70 117.00 72.20 
5.859a 0.015 
oral hypoglycemic 26.00 22.40 19.00 41.30 45.00 27.80 
BMI Category 
Obese 79.00 68.10 31.00 67.40 110.00 67.90 
3.318a 0.345 
Overweight 26.00 22.40 8.00 17.40 34.00 21.00 
Normal weight 11.00 9.50 6.00 13.00 17.00 10.50 
Underweight 0.00 0.00 1.00 2.20 1.00 0.60 
* Insulin resistance were done for 102 patients. 
Table 4: Independent predictors of the presence of vitamin D deficiency.  
The 3 variables  associated with  
vitamin D deficiency 
B coefficient values P value. 
DM on insulin therapy -0.760 0.088 
Lower C Peptide level 4.022 0.000 
Lower C Peptide Index (CPI) value -0.021 0.971 
 
Figure 2: Association between C peptide level and presence of insulin resistance. 
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P-value High (n=77) low  (n=85) 
Mean ± SD Mean ± SD 
BMI 34.11 ± 7.34 32.95 ± 7.31 0.316 
Systolic BP 127.47 ± 16.19 129.76 ± 21.87 0.446 
Diastolic BP 78.96 ± 10.04 80.00 ± 11.85 0.547 
Fasting blood sugar 159.16 ± 74.72 188.62 ± 90.95 0.025 
C peptide (ng/mL) 5.26 ± 3.91 0.54 ± 0.78 0.000 
25 (OH) D (ng/mL) 10.25 ± 6.05 7.47 ± 4.36 0.001 
HOMA %B 117.12 ± 81.88 26.95 ± 13.65 0.000 
HOMA IR 4.83 ± 4.42 1.96 ± 1.40 0.000 
 
 
Figure 3: Association between C Peptide Index (CPI) and presence of Insulin resistance. 
 
DISCUSSION: 
The prevalence of hypovitaminosis D is 
common among postmenopausal women 
particularly those with diabetes [26]. The results 
of our study showed that the majority of diabetic 
elderly female non-supplemented patients have 
suboptimal vitamin D level. In our study, vitamin 
D insufficiency was defined as a 25(OH)D level 
< 30ng/ml, which is in accordance with the 
recommendation of International Osteoporosis 
Foundation (IOF). The study showed that the 
prevalence of vitamin D deficiency is 71.2%, 
vitamin D insufficiency is 28.2% and vitamin D 
sufficiency is 0.6%, these results support other 
previous studies in this field at various 
countries, including sunny regions of the world 
and neighboring countries [26, 27]. In a recent 
study, the prevalence of hypovitaminosis D was 
higher in diabetic patients than in control 
Walaa W. Aly et al., IJOAR, 2018 1:15
IJOAR: http://escipub.com/international-journal-of-aging-research/                        8
subjects (90% vs. 83%; p<0.01) [28]. It affects 
89% of non-supplemented postmenopausal 
women with T2DM [37]. Deepika et al. [29] 
showed that patients with T2DM have a very 
low serum 25(OH)D level and almost all of the 
patients had vitamin D insufficiency or 
deficiency.  
Vitamin D deficiency is thought to influence DM 
pathogenesis by affecting either β-cell function, 
insulin sensitivity, or both [30]. 
Role of vitamin D in insulin secretion  
Vitamin D deficiency is associated with 
impaired insulin secretion, which is a high-risk 
factor for diabetes [31]. The level of Vitamin D 
is reported to be lower in diabetic patients than 
in non-diabetics [9] as vitamin D plays an 
important role in beta cell functions [32]. 
Endogenous insulin secretion can be measured 
by several indices (indices of insulin secretion) 
including fasting serum C peptide level, HOMA 
%B and CPI [24, 33-34]. We found statistically 
significant higher prevalence of vitamin D 
deficiency among diabetics on insulin therapy in 
comparison to those on oral hypoglycemic 
drugs. There was statistically significant 
difference between means of 25(OH)D as 
regards CP level and CPI. Mean serum 
25(OH)D (ng/mL) is higher among the high C 
peptide category than low C peptide one being 
10.19 vs. 6.07 among the 2 categories, 
respectively (P value 0.00). Subsequently, 
there was significant difference as regards 
vitamin D status and fasting serum C peptide 
level categories as majority of patients with low 
C peptide level (98.3%) had vitamin D 
deficiency (P value 0.00), also mean HOMA 
%B was higher among the high C peptide 
category than the normal C peptide one, 126.06 
vs. 62.74 resp with statistically significant 
difference (P value 0.00). Current study found a 
statistically significant association between low 
C peptide level and presence of vitamin D 
deficiency (P value 0.000), that is consistent 
with a large prospective, randomized, double-
blind, placebo-controlled clinical trials [35 - 36]. 
The current study showed that in comparison to 
patients on oral hypoglycemic therapy, patients 
on insulin therapy had significantly lower serum 
25(OH) vitamin D levels. There was statistically 
significant association between insulin therapy 
and vitamin D deficiency (P value 0.01) as the 
majority of patients on insulin therapy had 
vitamin D deficiency 90 patient out of 116 with 
odds ratio 2.4.  
Similarly, considering CPI as an index of 
endogenous insulin secretion [18], we found a 
positive correlation between serum 25 (OH) D 
and CPI value and a significant association 
between low serum 25(OH)D levels and low 
CPI, mean serum 25(OH)D was 10.25 ± 6.05 
vs. 7.47 ± 4.36 (P value 0.00) among high and 
low CPI categories, respectively. 
Role of vitamin D in insulin sensitivity 
To determine presence of insulin resistance, 
HOMA2 calculation was done for 102 patients, 
who had serum C peptide above 0.6ng/ml and 
showed that 69 patients (67.6%) had insulin 
resistance and 33 patients (32.4%) had no 
insulin resistance. Although the majority of 
studied population were insulin resistant, the 
present study couldn’t demonstrate significant 
association between hypovitaminosis D and 
presence of insulin resistance, but we 
demonstrated a negative correlation between 
serum 25(OH)D and  HOMA-IR (r = -0.048 , p 
value 0.62) that is supported by various studies 
including NHANES III which disclosed that 
serum 25(OH)D was inversely associated with 
measures of insulin resistance including HOMA 
IR [37]. Chandler et al. [35] reported that 
vitamin D intake was inversely associated with 
HOMA-IR and the relationship was independent 
of age, total body fat, and energy intake. In the 
Canadian Prospective Metabolism and Islet cell 
Evaluation (PROMISE) study cohort [38], a 
significant negative correlation was found 
between serum 25(OH)D and HOMA-IR (r = -
0.29, p < 0.001). 
Since insulin secretion and insulin resistance 
are positively correlated in type 2 diabetes, C-
peptide is positively correlated with insulin 
resistance [39]. One of the valuable finding of 
Walaa W. Aly et al., IJOAR, 2018 1:15
IJOAR: http://escipub.com/international-journal-of-aging-research/                       9
the current study is demonstration of the role of 
C peptide level as an indicator for insulin 
resistance that is supported by several findings. 
All patients with high C peptide had insulin 
resistance and patients with low C peptide had 
no Insulin resistance. There is statistically 
significant difference (P value 0.00) as regards 
C peptide level among BMI categories, being 
highest among obese patients. We 
demonstrated that mean HOMA IR was higher 
among high CPI category 4.83 ± 4.42 vs. 1.96 ± 
1.40. with significant difference (P value 0.00) 
and significant association between high CPI 
value and presence of insulin resistance (Odds 
Ratio for Insulin resistance was 6.27). 
Effect of hypovitaminosis D on glycemic 
control  
At the current study, we used FBS as an 
indicator for glycemic control, and  based on it,  
patients were divided into high FBS:  FBS 100 
mg/dl or more (no=136) and patients with 
normal FBS: FBS less than 100 mg/dl (no=26) 
to demonstrate any difference between the 2 
groups as regards serum 25(OH)D, insulin 
status and cardiovascular risk including obesity 
and hypertension. There was no statistical 
difference in serum 25(OH)D level among the 2 
categories as regards 25(OH)D. Mean serum 
25(OH)D level is 8.95± 5.69 in the high FBS 
category and 7.97± 3.46 in the normal FBS 
category (P= 0.24). 
Relation between hypovitaminosis D and 
obesity 
One relevant finding of the present study was a 
negative correlation between serum 25 (OH)D 
and BMI (r = -0.059, p 0.457). Several studies 
have shown that patients with hypovitaminosis 
D had higher prevalence of overweight or 
obesity when compared to patients with normal 
25(OH)D status [40]. Furthermore, obesity is 
associated with low serum 25(OH)D levels [41-
42]. Raška et al. [27] found significant negative 
association between 25(OH)D levels and BMI 
(p=0.01) 
We have demonstrated the relation between 
increased BMI and vitamin D status, insulin 
resistance, glycemic control and blood pressure 
for diabetic elderly women.  
Concerning serum 25(OH)D level, mean 
25(OH)D levels is lowest among obese and 
overweight women (p value 0.35), that is 
concordant with most of the published studies 
which report the inverse relation between BMI 
and vitamin D. Several clinical and 
epidemiological studies reported that obese 
subjects have lower serum concentrations of 
25(OH)D with a negative correlation of vitamin 
D concentrations with BMI and waist 
circumference [43, 44]. There was also an 
inverse association between 25(OH)D 
concentration and BMI [45]. A study involving 
243 adults reported a decrease of 0.74 nmol/l 
of serum 25(OH)D per 1 kg/m2 increase in BMI 
[46]. 
Relation between hypovitaminosis D and 
HTN   
The majority of study population (114 patients) 
had history of hypertension and were on 
antihypertensive medication. We demonstrated 
a negative correlation between serum 25(OH)D 
level and systolic hypertension (r = -0.056, p 
0.477). several observational studies [47, 48] 
have suggested links between low 25(OH)D 
levels and a subsequent higher risk for 
hypertension. The current study shows an 
inverse correlation between 25(OH)D and 
systolic blood pressure that is consistent with 
several studies which demonstrated association 
between arterial hypertension and 
hypovitaminosis D [49,50]. Previous studies 
showed negative correlation between serum 
25(OH)D level and blood pressure [51,52]. The 
prevalence of arterial hypertension was also 
associated with reduced serum 25(OH)D levels 
in several studies [53, 54]. 
Relation between hypovitaminosis D and 
CVD 
The Third National Health and Nutrition 
Examination Survey revealed that 25(OH)D 
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levels are associated with important 
cardiovascular disease risk factors. The 
prevalence of diabetes mellitus (odds ratio 
1.98), obesity (odds ratio 2.29), and arterial 
hypertension (odds ratio 1.30) were all 
significantly greater in the lower quartiles of the 
25(OH)D serum levels than in the higher 
quartiles (< 0.001 for all) [11]. Epidemiologic 
studies have reported a trend toward higher 
prevalence of ischemic heart disease and 
hypertension with increasing distance from the 
equator, and these higher rates are attributed to 
the higher rates of vitamin D deficiency in 
regions with less exposure to sunlight [55, 56]. 
At the current study, the failure to demonstrate 
the association between hypovitaminosis D and 
certain cardiovascular disease could be 
attributed to the absence of vitamin D 
sufficiency group to compare with 
hypovitaminosis D groups. 
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